Replies to post #204374 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Interesting thought process.. much to "chew on".

[XenaLives]

Good observation ...

Going back to the wording in the article:

A rare disease company can get away with smaller, less expensive clinical trials. But that’s not the case with Alzheimer’s, a fatal disease shared by roughly 5.8 million Americans and anticipated to affect three times that amount by 2050.

The more people that are impacted by a specific disease or condition, the larger the clinical trial needed to collect data and the higher the cost. Biogen and Eisai have enrolled around 1,600 people in each of their two most recent Alzheimer’s clinical trials. A trial of that size can cost anywhere from $75 million to $300 million, according to experts.

This misconception could be a big factor in keeping investors and some on the Street from taking Anavex seriously.

[plexrec]

jimmy--" At some point AVXL will go ballistic faster "--excellent post--our day is getting nearer !!!!!

[jmvho]

jimmy667 post#204374

Great post and I completely agree !

TGD knows what he's got ( as he is behind the curtain ) and I believe he is intent on turning AVXL into an extremely large company. As you say, he is " running silent and deep " right now and is purposely avoiding the distractions ( frivolous lawsuits, hostile takeover attempts, etc. ) that could result from putting out Biogen-like pump pieces. He knows the only thing that has credibility with the scientific and medical communities, and with Wall Street, are trial results. And, I agree with you that TGD is setting up a 1-2 punch ( Rett the PDD missiles " fired from a submerged position " ) that will both vaporize the shorts and simultaneously provide great protection from unwanted takeover attempts as institutional buying floods in and the share price skyrockets.

With 2-73 having been in the Australian AD trial for 4+ years, it seems TGD feels 2-73 has a very good of early, conditional approval following successful phase 2 trials for Rett and PDD in Australia, and given the $1 million stockpile of product and the shelf registration, it appears he is preparing to go it alone for those two indications. AD approval should follow about a year later but in light of the huge unmet need and having all the data from the extended AD trial, I wouldn't rule out early, conditional approval for AD.

So, although it's hard at times to be patient, given the current size of the company and its realistic capabilities at this time, and the obvious cabal manipulation, I think TGD is playing this exactly right - run silent and focus on completing the trials.

It's almost mind boggling to think what Anavex could be worth in five years.

In Missling I Trust !!

jmvho